Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
A phase 3 trial of Tarlatamab in small-cell lung cancer, run by Amgen, now recruiting.
Overview
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) is a phase 3 interventional study registered as NCT07778316 by Amgen, with 400 participants planned, started 2026-08-31 and due to reach its primary completion in 2027-09-24. Interventions recorded: Tarlatamab. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialStudy Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialStudy Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialA Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialA Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small
Shares Tarlatamab, Amgen, Small-cell lung cancer.
- TrialA Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Shares Amgen, Small-cell lung cancer.
- TrialPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Shares Amgen, Small-cell lung cancer.
- TrialStudy Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Shares Amgen, Small-cell lung cancer.